Recent Updates
Recently added Catalysts
PCRX Positive Sentiment

Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference

Key Takeaway: Pacira BioSciences, Inc. will participate in the 2023 RBC Capital Markets Global Healthcare Conference, scheduled for May 16, 2023, in New York. The event will feature an analyst-led fireside chat, and live audio will be available on the company's website. Alongside this event, Pacira emphasizes its mission to provide non-opioid options for pain management, showcasing its three commercial-stage treatments. Post-conference, a replay of the webcast will be accessible for two weeks.
Price reaction · baseline $42.26 (2023-05-08 close) · hit after-hours · clean, no other PCRX news in the window
day 0 close · peak
+0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Pacira BioSciences is participating in a well-regarded conference, enhancing its visibility.
  • The company's commitment to non-opioid options aligns with current healthcare trends.
  • Pacira offers innovative treatments that address significant pain management needs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
5.7%
average across 5 past catalysts
Lead asset
FX006
Phase 2 · Osteoarthritis of the Shoulder

Full Press Release Details

TAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference at 3:05 PM ET on Tuesday, May 16, 2023 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Frequently Asked Questions

When is Pacira BioSciences participating in the RBC Conference?

Pacira BioSciences will participate on May 16, 2023, at 3:05 PM ET.

How can I access the RBC Conference webcast?

The live audio can be accessed through the Events page on Pacira's website.

What is the goal of Pacira BioSciences?

Pacira aims to provide non-opioid options and redefine opioids as rescue therapy.

What are Pacira's commercial-stage non-opioid treatments?

They include EXPAREL®, ZILRETTA®, and ioveraº® for pain management.

What conditions does Pacira address?

Pacira develops interventions for chronic pain, cardiac electrical storms, and spasticity.

Last updated: May 9, 2023